Alumis Inc

ALMS is in a Stage 4 decline with a breakdown under short EMAs and now approaches the rising 200-day SMA. Extreme oversold readings grant mean-reversion permission for a medium-term bullish stance, but price remains extended below key EMAs with no clear reversal. Execution should await a bounce and acceptance at the 200-day SMA. A failure to hold that support would negate the bullish setup.

• ↑Envudeucitinib ONWARD3 trial: 75% PASI 90 & 54% PASI 100 at 48 weeks
• ↑$502.3M cash & equivalents support operations into Q4 2027
• ↓Q2 2026 revenue $1.7M down 37% YoY vs. $3.47M consensus